Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Morrow

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Open Forum Infectious Diseases|September 29, 2021
Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIVJose R Castillo-Mancilla, Mary Morrow, Ryan P Coyle, et al.
AIDS (London, England)|June 15, 2021
Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherenceMary Morrow, Samantha MaWhinney, Ryan P Coyle, et al.
Pharmacotherapy|June 16, 2022
Cumulative tenofovir diphosphate exposure in persons with HIV taking single- vs. multiple-tablet regimensRyan P Coyle, Mary Morrow, Samantha MaWhinney, et al.
BMJ Open|July 26, 2022
Safety, feasibility and initial efficacy of an app-facilitated telerehabilitation (AFTER) programme for COVID-19 survivors: a pilot randomised studyJacob John Capin, Sarah E Jolley, Mary Morrow, et al.
Open Forum Infectious Diseases|October 19, 2020
Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency VirusFrances Vernon, Mary Morrow, Samantha MaWhinney, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 17, 2020
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS StudyJenna Yager, Jose Castillo-Mancilla, Mustafa E Ibrahim, et al.
AIDS (London, England)|September 5, 2021
Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarateJenna L Yager, Kristina M Brooks, Jose R Castillo-Mancilla, et al.
The Journal of Antimicrobial Chemotherapy|January 23, 2019
Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapyKatherine Frasca, Mary Morrow, Ryan P Coyle, et al.
AIDS (London, England)|September 14, 2018
Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoringCatherine A Koss, Albert Y Liu, Jose Castillo-Mancilla, et al.
AIDS Research and Human Retroviruses|October 27, 2022
Demographic and Clinical Characteristics of Persons with HIV with Viral Load:Adherence Mismatch Who Are at Risk of Future ViremiaEitan Grinsteiner, Mary Morrow, Samantha Mawhinney, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Open Forum Infectious Diseases|September 29, 2021
Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIVJose R Castillo-Mancilla, Mary Morrow, Ryan P Coyle, et al.
AIDS (London, England)|June 15, 2021
Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherenceMary Morrow, Samantha MaWhinney, Ryan P Coyle, et al.
Pharmacotherapy|June 16, 2022
Cumulative tenofovir diphosphate exposure in persons with HIV taking single- vs. multiple-tablet regimensRyan P Coyle, Mary Morrow, Samantha MaWhinney, et al.
BMJ Open|July 26, 2022
Safety, feasibility and initial efficacy of an app-facilitated telerehabilitation (AFTER) programme for COVID-19 survivors: a pilot randomised studyJacob John Capin, Sarah E Jolley, Mary Morrow, et al.
Open Forum Infectious Diseases|October 19, 2020
Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency VirusFrances Vernon, Mary Morrow, Samantha MaWhinney, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 17, 2020
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS StudyJenna Yager, Jose Castillo-Mancilla, Mustafa E Ibrahim, et al.
AIDS (London, England)|September 5, 2021
Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarateJenna L Yager, Kristina M Brooks, Jose R Castillo-Mancilla, et al.
The Journal of Antimicrobial Chemotherapy|January 23, 2019
Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapyKatherine Frasca, Mary Morrow, Ryan P Coyle, et al.
AIDS (London, England)|September 14, 2018
Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoringCatherine A Koss, Albert Y Liu, Jose Castillo-Mancilla, et al.
AIDS Research and Human Retroviruses|October 27, 2022
Demographic and Clinical Characteristics of Persons with HIV with Viral Load:Adherence Mismatch Who Are at Risk of Future ViremiaEitan Grinsteiner, Mary Morrow, Samantha Mawhinney, et al.
Pageof 4